Dyax Corp. Announces Expansion of Research Agreement with Trubion Pharmaceuticals, Inc.
"We are excited Trubion has expanded its research agreement to further take advantage of our proprietary phage display technology," commented Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax. "This expanded agreement continues to validate our technology as a powerful tool for accelerating discovery and development of therapeutic agents and, additionally, confirms the success of our Licensing and Funded Research Program (LFRP)."
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.